Chitosan-Coated Solid Lipid Nano-Encapsulation Improves the Therapeutic Antiairway Inflammation Effect of Berberine against COPD in Cigarette Smoke-Exposed Rats

Table 2

Pharmacokinetic parameters in the treated rats after a single oral dose administration of Ber-loaded SLN-chitosan nanoparticles and pure suspension of berberine.

	Unit	Ber-loaded SLN-chitosan nanoparticles	Berberine
Dose	mg/kg	50	50
Cmax	ng/ml	479 ± 13	112 ± 14
Tmax	h	3	0.5
AUC	ng.h/ml	2973 ± 76	647 ± 77
BAR		—	4.6-fold

AUC, area under the berberine plasma concentration-time curve; BAR, the relative bioavailability of oral administration of Ber-loaded SLN-chitosan nanoparticles compared with the pure berberine suspension; C_max, the maximum plasma concentration of berberine after oral administration; T_max, the time to maximum plasma concentration of berberine.